澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ALTERITY THERAPEUTICS LTD

0.430

+0.0051.18%

成交量：10.52萬

成交額：4.43萬

市值：9,352.86萬

市盈率：-3.87

高：0.430

開：0.420

低：0.420

收：0.425

52周最高：0.785

52周最低：0.350

股本：2.18億

流通股本：1.49億

量比：0.29

換手率：0.07%

股息：- -

股息率：- -

每股收益(TTM):-0.111

每股收益(LYR):-0.111

淨資產收益率：-54.98%

總資產收益率：-34.08%

市淨率：2.19

市盈率(LYR):-3.87

資料載入中...

總覽公司新聞資訊公告

Alterity Therapeutics：FDA同意單一關鍵性三期試驗加驗證證據可支持Ath434治療多系統萎縮症的批准

早報｜MiCA 寬限期 7 月 1 日到期；Kalshi 世界盃首周交易量破 51 億美元創紀錄

Alterity Therapeutics獲FDA積極反饋：ATH434多系統萎縮三期項目二次C類會議成果顯著

Alterity Therapeutics任命資深生物技術高管Ann Cunningham加入董事會

Alterity Therapeutics將在美國神經病學學會年會發表重磅突破性口頭報告

Alterity Therapeutics獲FDA積極反饋：ATH434三期臨床試驗項目Type C會議成果喜人

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/ATH.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.43,"timestamp":1789539120000,"preClose":0.425,"halted":0,"volume":105207,"delay":0,"changeRate":0.011764705882352951,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":149498066,"shares":217508326,"eps":-0.1112,"marketStatus":"未開盤","change":0.005,"latestTime":"09-16 16:12:00 AEST","open":0.42,"high":0.43,"low":0.42,"amount":44331,"amplitude":0.023529,"askPrice":0.44,"askSize":3651,"bidPrice":0.415,"bidSize":2412,"shortable":3,"etf":0,"ttmEps":-0.1112,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.425,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.290577,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATH.AU","preClose":0.425,"auctionPrice":0.42,"auctionVolume":11904,"auction":3,"marketStatus":"盘后竞价","timestamp":1789538444561}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":149498066,"roa":"-34.08%","roe":"-54.98%","lyrEps":-0.1112,"volumeRatio":0.290577,"shares":217508326,"dividePrice":0,"high":0.43,"amplitude":0.023529,"preClose":0.425,"low":0.42,"week52Low":0.35,"pbRate":"2.19","psRate":"25.91","week52High":0.785,"institutionHeld":0,"latestPrice":0.43,"committee":-0.204354,"eps":-0.1112,"divideRate":0,"volume":105207,"delay":0,"ttmEps":-0.1112,"open":0.42,"prevYearClose":0.4,"prevWeekClose":0.46,"prevMonthClose":0.505,"prevQuarterClose":0.575,"fiveDayClose":0.505,"twentyDayClose":0.505,"sixtyDayClose":0.575},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-06-03","symbol":"ATH.AU","defaultRemindTime":1780444800000,"type":"split","dateTimestamp":1780408800000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142876485","title":"Alterity Therapeutics：FDA同意單一關鍵性三期試驗加驗證證據可支持Ath434治療多系統萎縮症的批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1142876485","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142876485?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 18:15","pubTimestamp":1783419300,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics宣布，美国食品药品监督管理局（FDA）已同意，一项单一的关键性三期临床试验，辅以确证性证据，可能足以支持其候选药物Ath434用于治疗多系统萎缩症（MSA）的上市批准。这一监管反馈为该公司推进该疗法的临床开发路径提供了明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643878763","title":"早報｜MiCA 寬限期 7 月 1 日到期；Kalshi 世界盃首周交易量破 51 億美元創紀錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2643878763","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643878763?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 09:04","pubTimestamp":1781571864,"startTime":"0","endTime":"0","summary":" 6 月 15 日市场重要事件一览 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2271606","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HECO","DUST","LU2237438978.USD","LU1599440770.SGD","SGCmain","BK4207","IAU","IE0004091025.USD","02513","BK4566","ATH.AU","DAPP","159934","MGCmain","CIB","LU0158827948.USD","LU0731783048.USD","LU0912757837.SGD","LU1430594728.SGD","LU1732800096.USD","LU1116320737.USD","LU0143551892.USD","BK1117","LU0070217475.USD","IE00BVYPNV92.GBP","BEGS","GCmain","GDX","LU2462591277.SGD","DBC","CME","BKCH","BTGD","IE0004086264.USD","LU0950375773.USD","LU1732799900.SGD","IE000M9KFDE8.USD","LU0823417653.USD","IE00B42XCP33.USD","NUGT","LU0265550359.USD","518880","LU0390136736.USD","AFA","GLD","IE00BDGV0183.EUR","IE00B3PB1722.GBP","LU0823417737.USD","LU1228905037.USD","SGUmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173810522","title":"Alterity Therapeutics獲FDA積極反饋：ATH434多系統萎縮三期項目二次C類會議成果顯著","url":"https://stock-news.laohu8.com/highlight/detail?id=1173810522","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173810522?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 19:40","pubTimestamp":1777290057,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics Ltd（ATH.AU）宣布，其针对多系统萎缩症的ATH434三期临床项目在第二次C类会议后，获得了美国食品药品监督管理局（FDA）的积极反馈。\n此次会议重点讨论了ATH434三期临床试验的设计方案与监管路径。FDA对该公司提出的开发计划表示认可，并就关键研究要素提供了建设性指导意见。这一进展标志着ATH434项目向正式开展三期临床研究迈出重要一步。\n多系统萎缩症是一种罕见的神经退行性疾病，目前尚无获批的有效治疗方法。ATH434作为一种小分子疗法，旨在通过减少大脑中的异常铁积累来延缓疾病进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105645000","title":"Alterity Therapeutics任命資深生物技術高管Ann Cunningham加入董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1105645000","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105645000?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 19:26","pubTimestamp":1776425175,"startTime":"0","endTime":"0","summary":"生物制药公司Alterity Therapeutics Ltd宣布一项重要人事任命，资深生物技术领域高管Ann Cunningham正式加入其董事会。此次任命标志着公司进一步加强治理团队的专业深度，Cunningham女士在生物技术行业数十年的领导经验将为Alterity Therapeutics的战略发展注入新的活力。Alterity Therapeutics董事会认为，Cunningham女士的加入将有效提升公司在临床开发阶段的决策能力，并为其全球业务拓展带来宝贵经验。这一人事变动也体现了公司致力于吸纳行业顶尖人才，以推动其创新疗法研发进程的坚定承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121189123","title":"Alterity Therapeutics將在美國神經病學學會年會發表重磅突破性口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=1121189123","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121189123?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 19:27","pubTimestamp":1776338829,"startTime":"0","endTime":"0","summary":"生物制药公司Alterity Therapeutics Ltd（ASX: ATH）宣布，其研究成果入选美国神经病学学会（AAN）年度会议的重磅突破性环节，并将进行口头报告。\n该环节专门展示具有高度创新性和临床意义的最新研究数据，凸显了Alterity Therapeutics在神经科学领域的前沿探索获得国际权威学术认可。此次报告将为医学界带来其在神经退行性疾病治疗方面的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161808099","title":"Alterity Therapeutics獲FDA積極反饋：ATH434三期臨床試驗項目Type C會議成果喜人","url":"https://stock-news.laohu8.com/highlight/detail?id=1161808099","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161808099?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 18:19","pubTimestamp":1774865967,"startTime":"0","endTime":"0","summary":"生物制药公司Alterity Therapeutics Ltd近日宣布，其针对ATH434的三期临床试验项目已获得美国食品药品监督管理局（FDA）的积极反馈。此次反馈源于双方成功举行的Type C会议，标志着该疗法在监管审批道路上取得关键进展。\nATH434作为公司核心研发项目，此次FDA的认可为其后续临床开发及潜在上市奠定了坚实基础。公司表示将依据监管意见推进三期试验方案优化，加速神经退行性疾病治疗领域的创新突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}